Everything About CBD - What Is It? Complete Guide 2026

Cannabidiol, abbreviated CBD, is one of the compounds produced by industrial hemp. It does not intoxicate, is not listed in Polish controlled substances registers, and since 2018 has one registered medicinal form. However, so much marketing has grown around it that it is hard to separate what has been measured from what was invented for labeling purposes. This guide leads through the definition, mechanism of action, product forms, dosing, legal status, and principles of choosing oil. Behind every number here is work that can be opened and read, and where studies are lacking, it is stated plainly instead of softened by generalities. You will also see which popular statistics were removed from this text in editing and why none had a substitute. After reading, you will know what to realistically expect from cannabidiol.

KEY INFORMATION
• CBD does not stimulate the CB1 receptor like THC; in cell studies, it weakens the action of its agonists as a negative allosteric modulator (Laprairie 2015).
• The only measured absolute bioavailability of cannabidiol in humans concerns inhalation and is 31%; no such measurement exists for oral or sublingual routes (Millar 2018).
• A fat-rich meal increased CBD exposure 4.85-fold in Cmax and 4.2-fold in AUC (Taylor 2018).
• The Polish 0.3% THC threshold in industrial hemp counts as the sum of delta-9-THC and THCA, not delta-9-THC alone (art. 4 point 5 of the Act on Counteracting Drug Addiction).
• The only registered cannabidiol drug covers exclusively drug-resistant epilepsies; other uses have no registration.

What is CBD and where does it come from?

CBD, or cannabidiol, is a compound produced by industrial hemp Cannabis sativa L. It does not intoxicate because it does not stimulate the CB1 receptor like THC. In the living plant, it mainly occurs as the acidic form CBDA, and only heating converts it to the active form. The molecular formula and structure are explained in the next section.

The raw material for legal products is industrial hemp, i.e., varieties with low THC content. Their cultivation in Poland requires registration with the regional director of KOWR. Extract is obtained from dried flower heads and then diluted with a carrier oil, most often fractionated MCT coconut oil. The oil pressed from hemp seeds does not contain significant cannabidiol and is not the same product, although label names can be misleading.

The cannabidiol content in the flower depends on the variety, harvest time, and drying method, so the only reliable number is from the certificate of analysis of a specific batch. The often-repeated advertising claim that cannabidiol constitutes 10-20% of flower mass has no source that can be opened and verified. We removed it from this text along with other unsupported numbers.

It is worth noting the difference between CBDA and CBD because it explains something that surprises beginners. Fresh dried material mainly contains the acidic form and releases little of it when brewed in water because the acid dissolves poorly in fat. Only heating, and with long storage also time itself, detaches the carboxyl group and converts CBDA to CBD. Therefore, the same dose of dried material behaves differently in a vaporizer, in an infusion, and in oil where the extract is already processed.

The law lists purposes for which industrial hemp may be cultivated, and the list is long: from textile to food uses. Hence, raw material from one plantation goes into products of completely different categories.

What is the molecular structure of cannabidiol?

Cannabidiol is a phytocannabinoid with the molecular formula C21H30O2: 21 carbon atoms, 30 hydrogen atoms, and 2 oxygen atoms. The molar mass is 314.46 g/mol (PubChem, NCBI). In the plant, it accumulates mainly in trichomes, i.e., resin glands on female flower heads, and its direct precursor is cannabidiolic acid.

Cannabidiolic acid is formed from the universal precursor, cannabigerolic acid. The same precursor is at the start of other cannabinoids, which we discuss more in the text about cannabigerol.

The full structure of cannabidiol was described by Rafael Mechoulam’s team at the Hebrew University of Jerusalem, and the THC structure was established by the same team only afterward. This allowed the first spatial comparison of both molecules.

The distinction between the acidic and decarboxylated forms has practical significance, though it rarely appears on labels. Laboratory results usually provide both values separately, and the producer may calculate total content considering mass lost during decarboxylation. Therefore, two products with the same number on the package may describe two different quantities. What matters is what exactly the certificate measures, not the number in the product name.

How does CBD differ from THC?

The difference is not in the molecular formula, which is identical, but in how each compound interacts with the CB1 receptor. THC stimulates it directly, causing intoxication. Cannabidiol behaves oppositely in cell studies: it weakens the strength and efficacy of CB1 agonists, acting as a negative allosteric modulator (Laprairie 2015).

The practical consequence is this: a full-spectrum product contains trace THC within legal limits but can still be detected by sensitive tests with intensive daily use. Professionally tested individuals usually choose variants declaring zero THC content and confirm it with batch certificates. This is the only way to replace marketing claims with verifiable numbers.

Identical molecular formula with different effects is often treated as a curiosity but is the core issue. Whether a molecule stimulates the receptor depends on its spatial shape, i.e., the arrangement of the same atoms. The receptor recognizes geometry, not composition. Hence, two compounds with the same molecular weight can have vastly different effects, and copying the formula from the package proves nothing.

The second difference concerns how both molecules behave together. Cannabidiol given with THC weakened the receptor’s response to the latter in cell studies. Therefore, full-spectrum extract is not a simple sum of components, and comparing it with isolate based on cannabidiol content in milligrams alone misses the point.

How does CBD work in the body?

Cannabidiol acts indirectly on the endocannabinoid system. This system consists of CB1 and CB2 receptors, endogenous cannabinoids mainly anandamide and 2-AG, and enzymes that produce and degrade them. It is a modulatory network, not a switch, tuning synaptic function and neurotransmission in the developing brain (Lu and Mackie 2021).

Cannabidiol itself binds weakly to CB1 and CB2. Instead, it changes how the CB1 receptor responds to the body’s own transmitters. This was confirmed in cell lines: cannabidiol presence reduced the efficacy and potency of 2-AG and THC and inhibited receptor internalization.

Beyond the endocannabinoid system, cannabidiol has several other molecular targets, including the serotonin 5-HT1A receptor, TRPV channels, and nuclear receptors from the PPAR family. However, a pharmacology review emphasizes that the number of possible binding sites does not replace clinical evidence, as most claimed benefits do not come from controlled studies (Britch 2021).

The popular explanation that cannabidiol raises anandamide levels by blocking FAAH enzyme is a hypothesis discussed in literature, not a consistently measured fact in humans. It is more honest in consumer texts to say that the mechanism of cannabidiol action in humans is not yet fully understood. How individual cannabinoids distribute among these pathways is shown in the text about how cannabinoids act on the human body.

The two receptor types are distributed differently. CB1 is dense in the central nervous system and responsible for most psychoactive effects of THC. CB2 predominates in immune cells and peripheral tissues. The system’s transmitters, anandamide and 2-AG, are produced on demand and act retrogradely, i.e., from the receiving neuron back to the sending one. This unusual direction explains why the endocannabinoid system functions as a brake tuner, not a transmitter.

This structure leads to caution in literature. Since the system affects sleep, appetite, pain perception, and inflammatory response simultaneously, a substance modulating it indirectly may produce dispersed effects hard to measure with a single indicator. Hence, cannabidiol studies more often show moderate changes at many points than a clear single result.

How is CBD extracted from hemp?

Cannabidiol is extracted from hemp biomass by two main methods: supercritical carbon dioxide and ethanol. The choice affects terpene profile, chlorophyll presence, and solvent residue risk - three things consumers perceive in taste, color, and lab results.

Supercritical extraction uses carbon dioxide in a state between gas and liquid, achieved under high pressure. In this state, it dissolves lipophilic cannabinoids and terpenes without thermal load, and evaporates completely after decompression. The result is a solvent-free concentrate. The cost is equipment expense and process complexity.

The ethanol method immerses biomass in food-grade alcohol, which extracts cannabinoids along with chlorophyll, then evaporates it by distillation. It is cheaper and more efficient at large scale but requires thorough solvent removal and more often damages delicate terpenes. Additional freezing and filtration steps remove most unwanted components.

Hydrocarbon solvents like butane or hexane are a separate issue. They are not used in legal food and cosmetic production, and their residues are harmful. This is one reason why independent lab test results are more important than declared extraction method on the label.

After extraction, the crude extract undergoes purification. Freezing removes waxes and lipids, distillation increases cannabinoid content, and THC removal is an additional step for THC-free products. Each step changes terpene proportions, so full-spectrum and broad-spectrum oils from the same biomass can differ in taste and smell more than the THC content difference alone would suggest.

What do clinical studies confirm about CBD?

The strongest data concern drug-resistant epilepsies, which led to drug registration. Outside this area, evidence is much weaker: from small trials, case series, or cell studies. A cannabidiol pharmacology review states this plainly, noting that the only product subjected to full pharmacokinetic and clinical evaluation is the drug registered for childhood epilepsies (Britch 2021).

Shannon’s series is often cited as evidence for insomnia efficacy but is a chart review without control group, with sleep results fluctuating over months. The authors conclude controlled studies are needed. This difference between observation and clinical trial is worth remembering with every advertisement.

The Dravet trial also shows the other side of the balance. Side effects were more frequent than placebo and included diarrhea, vomiting, fatigue, fever, drowsiness, and abnormal liver tests. More participants withdrew from cannabidiol than placebo. Efficacy and burden go together here, which is normal for a drug and unusual for a supplement.

What are the forms of CBD products?

Form determines two things: how fast the compound appears in blood and how precisely the dose can be measured. Other differences, including taste and convenience, are secondary. Market percentage breakdowns circulating in articles come from sales reports not publicly available, so we do not provide them here.

Oil remains the most controllable form because a graduated pipette allows doses below five milligrams and returning to them the next day. Gummies do not allow this, and cosmetics are not dosed forms at all. If you are just starting, begin with oil and add other forms once you know your suitable dose.

For vaporization, temperature is decisive. Too low does not release cannabinoids; too high causes burning, producing smoke with decomposition products instead of vapor. Devices with ten-degree increments allow control; one-button devices do not. This is also the only administration route with measured absolute bioavailability in humans, so comparisons with oral forms are not symmetrical.

Cosmetics require special attention because their declarations are often most vague. A sensible label states cannabidiol content in milligrams per entire package or per 100 grams. Phrases like “with hemp extract” say nothing, and hemp seed oil in ingredients is not the same as flower extract.

How much CBD really reaches the blood?

The answer is: for most forms, no one has measured this in humans. A systematic cannabidiol pharmacokinetics review searched 792 publications and found 24 with human data. Absolute bioavailability was reported only for inhalation, at 31%. No such measurement exists for other routes (Millar 2018).

This is important because a four-column table with values 6-15% oral, 13-19% sublingual, and 30-35% inhaled has circulated in Polish internet for years and appeared in previous versions of this entry. No paper supports it that can be opened. We removed it instead of correcting because no correct version of this table exists.

The same review provides other measured numbers: half-life from 1.4 to 10.9 hours after mucosal aerosol, 2 to 5 days with chronic oral dosing, and 31 hours after inhalation. Time to maximum concentration ranges from zero to four hours, and maximum concentration increases after meals and with fat formulations.

The scale of the latter was measured separately. In a phase 1 study, a fat-rich meal increased maximum cannabidiol concentration 4.85-fold and area under the curve 4.2-fold, with unchanged time to peak (Taylor 2018). The practical advice is simple: take oil with food and always the same way, or you compare incomparable days.

The same study provides data on accumulation. With twice-daily dosing, steady state was reached after about two days, and concentration increased 1.8 to 2.6 times. The final half-life was about 60 hours, while the effective half-life was 10 to 17 hours. The first describes residual elimination, the second the daily dosing rhythm.

This explains the advice to start assessment only after several days of regular intake. The first dose does not yet show the level at which the body stabilizes. The same mechanism explains why a break of several days and return to the same dose feels different than continuous use.

How to dose CBD?

No reference dose for non-medical use has been established, and no source provides one. The only numbers with coverage are doses used in specific studies linked to specific endpoints. The table below collects them to show how much they differ and how little they relate to package suggested portions.

From the two anxiety trials comes a counterintuitive conclusion: the dose-effect relationship is an inverted U shape. The middle dose worked, not the highest. So if a portion does not bring change, increasing it may not help and can be a step backward.

Practically, this means three things. Start with a small portion and change it no more often than every few days. Record the portion with time and meal because without this you cannot distinguish product effect from day of the week. Stick to one product during the trial because changing concentration also changes the oil matrix.

There is also a pharmacokinetic reason why increasing dose fails. In a dose-escalation study, exposure increased slower than dose: doubling the amount raised maximum concentration and area under the curve less than twofold. Doubling the portion does not mean doubling what reaches blood. It means doubling cost and higher likelihood of dose-dependent side effects.

Is CBD legal in Poland in 2026?

Yes. Cannabidiol is not listed in any psychotropic, narcotic, or new psychoactive substances lists. The word “cannabidiol” does not appear in the Minister of Health regulation of August 17, 2018 (consolidated text Dz.U. 2024 item 1139). Products from industrial hemp are legal if they meet the THC content threshold.

The threshold is defined by art. 4 point 5 of the Act on Counteracting Drug Addiction (consolidated text Dz.U. 2023 item 1939), as amended by the March 24, 2022 act (Dz.U. 2022 item 763). Industrial hemp plants have a sum of delta-9-THC and tetrahydrocannabinolic acid in flower or fruiting tops not exceeding 0.3% dry weight, rounded to one decimal place.

This distinction changes lab test results and is not a formality. The threshold concerns the sum, not delta-9-THC alone. Until May 6, 2022, the value was 0.20%, and since May 7, 2022, it is 0.3%; statements about 0.2% threshold are now only correct as historical facts with date.

The EU threshold has the same value but a separate basis: art. 4 para. 4 of Regulation 2021/2115, applied since January 1, 2023. Previously it was 0.2% under repealed Regulation 1307/2013. The correct phrasing is that the national threshold corresponds to the EU one, not that it derives from it.

Hemp seed food has separate limits expressed in milligrams per kilogram. For seeds and processed products, the highest allowed level is 3.0 mg/kg, and for seed oil 7.5 mg/kg. The level refers to the sum of delta-9-THC and THCA expressed as delta-9-THC. The basis is Annex I to Commission Regulation 2023/915, applied since May 25, 2023. Confusing these limits with the 0.3% threshold is the most common mistake in hemp-in-kitchen texts.

Finally, a distinction readers ask about most often. Cannabidiol is not a controlled substance, but HHC, hexahydrocannabinol, is. These are two different legal statuses, and no changes in lists reversed this. If a seller places both compounds side by side as equally legal, it signals they did not check the legal status.

When does CBD require a prescription and when not?

Products from industrial hemp sold as cosmetics, collectibles, or aromas are available without prescription. Pharmaceutical preparations with cannabidiol and cannabis herb other than industrial hemp, i.e., pharmaceutical raw material used in pharmacy compounding, require a prescription.

Access to pharmaceutical cannabis raw material was opened in Poland by the Act of July 7, 2017 (Dz.U. 2017 item 1458), effective November 1, 2017. Doctors issue prescriptions, and pharmacies prepare the drug. Cannabidiol bought without prescription does not require this procedure but is not reimbursed or supervised as a drug.

The food status remains unresolved. Cannabidiol undergoes the novel food procedure in the EU, which is not completed, so it cannot be sold as a dietary supplement. Hence the category of collectible products, a consequence of legal status, not a sales trick. We discuss this more in the text about CBD product regulations.

The same status limits communication. Producers cannot attribute medicinal effects or use health claims not approved. Statements like “treats anxiety” or “prevents disease” are illegal regardless of what studies on the molecule show.

For buyers, the collectible category has one real consequence. A product that is neither food nor drug formally is not subject to requirements proper to those categories, so quality depends solely on how the producer controls raw material and batches. Therefore, a certificate of analysis replaces supervision that does not exist. Without it, you buy a description, not a measurement result.

Where did CBD’s popularity come from?

CBD’s popularity was built on three things: discovery of the endocannabinoid system, one publicized patient story, and FDA drug registration. The first gave scientific basis, the next two gave publicity and drug status, together moving cannabidiol from research margins to store shelves where it mainly stands today as a consumer product.

The scientific basis came from identifying the endocannabinoid system. The CB1 receptor was identified first, then CB2, then endogenous cannabinoids anandamide and 2-AG. It turned out the body has its own signaling system that phytocannabinoids can affect. Without this discovery, CBD would remain a chemical curiosity.

The breakthrough image moment was Charlotte Figi’s story, a girl with Dravet syndrome whose conventional treatment failed, and parents turned to oil from a high-CBD, low-THC strain. The case reached nationwide US TV and sparked a wave of interest. The strain used was named Charlotte’s Web. A single case is not proof of efficacy but changed public discussion direction.

Proof came later and from elsewhere. A randomized trial in children with Dravet syndrome showed cannabidiol’s superiority over placebo (Devinsky 2017), and in June 2018 FDA registered Epidiolex for Dravet and Lennox-Gastaut syndromes (FDA, 2018). This was the first approved drug derived solely from cannabis, changing CBD’s status from alternative wellness to a pharmacological substance with a defined indication.

Between these three moments and today’s store shelf, however, a gap formed worth seeing. Registration covered two rare epilepsy syndromes and one drug form, with doses in milligrams per kilogram body weight, while the consumer market grew around completely different uses and doses. Popularity preceded evidence instead of arising from it, explaining most discrepancies between packaging promises and study findings.

How to choose a good CBD product?

One thing decides: a certificate of analysis issued by an independent lab for the batch you hold. Without it, you do not know how much cannabidiol is in the bottle or what else it contains. Price and declared concentration do not replace this document because both numbers are set by the seller, not the lab.

• The batch number on the label must be found in the certificate; a “model” certificate for the whole product line confirms nothing.
• The certificate should include cannabinoid contents, heavy metals, pesticides, solvent residues, and microbiological contamination results.
• The test date should be close to the batch production date, not years old.
• The extraction method may be described in the certificate and allows verifying the seller’s declaration.

The second decision concerns extract type. Isolate is purified cannabidiol without other plant components. Broad spectrum contains other cannabinoids and terpenes but no THC. Full spectrum preserves natural proportions with trace THC within legal limits. The choice mainly depends on whether you are subject to drug testing.

The entourage effect, i.e., the hypothesis that plant components enhance each other, remains a hypothesis discussed in reviews, not a measured quantity. Numbers like “30-40% stronger than isolate” come from no study and were removed from this text. If a seller provides such a value, ask for the source paper.

Also pay attention to the relation between declaration and measurement. The percentage on the bottle is the producer’s declaration, and the certificate gives the measured result for a specific batch. These two numbers can differ within analytical tolerance, but a discrepancy of tens of percent is not normal. Comparing takes a minute and is the only way to check if you pay for milligrams or for a label.

What are CBD side effects and interactions?

Cannabidiol is usually well tolerated but not inert. A clinical data review indicates the most common side effects are fatigue, diarrhea, and changes in appetite and body weight, noting this profile compares favorably to drugs used for the same indications (Iffland and Grotenhermen 2017).

A phase 1 dose-escalation study gave a similar picture. Most common events were diarrhea, nausea, headache, and drowsiness, all mild or moderate, with no severe cases or study discontinuations due to side effects.

A separate review including consumer use is more cautious. It reports nearly half of users experienced side effects, dose-dependent, including increased aminotransferase activity, drowsiness, sleep disturbances, infections, and anemia (Brown and Winterstein 2019).

The same review describes drug interaction mechanisms. Cannabidiol affects CYP3A4 and CYP2C19 enzymes and P-glycoprotein responsible for drug elimination, so interaction risk with commonly used drugs is high. Authors recommend considering lower primary drug dose, monitoring side effects, or alternative therapy. If you take chronic medications, decide on combining with cannabidiol with your doctor or pharmacist, not the seller.

The liver deserves a separate note. Increased aminotransferase activity appears in registration studies and consumer use reviews. In the Dravet trial, abnormal liver tests were more frequent with cannabidiol than placebo. People with liver disease should treat cannabidiol as a substance requiring supervision, not a neutral dietary supplement.

A common mistake is assuming that because something is plant-based, it does not interact. The mechanism described above works exactly as with synthetic drugs: inhibited enzyme breaks down the other drug more slowly, raising its concentration. Highest caution is needed with drugs with narrow therapeutic windows where small concentration changes alter effect.

How to start using CBD step by step?

The scheme below is a way to organize your own trial, not medical advice. Its point is to have a basis for decision after six weeks instead of just an impression. Change only one thing at a time because with two changes at once, you cannot tell which worked.

• Weeks 1 and 2: small portion once daily, at a fixed time, always with a fat-containing meal. Record sleep, tension, and mood in the morning on a scale from one to ten.
• Weeks 3 and 4: if nothing changed, increase portion by one step and keep it for two weeks. If daytime drowsiness appears, move the entire portion to evening instead of increasing.
• Weeks 5 and 6: maintain the effective portion and do not increase further. If no change, consider another form or stopping the trial rather than further increase.
• After completion: compare notes from the first and last week. Without this comparison, you only have memory, which systematically errs in such trials.

If unexplained symptoms appear, stop and consult a doctor. This especially concerns people taking drugs metabolized by CYP3A4 and those with liver diseases, as the liver processes cannabidiol and shows first deviations in tests.

The scheme has another less obvious function. It sets the moment when you can say “it does not work” and end the trial without feeling you lacked patience. Without such a limit, it is easy to keep increasing the dose, which with an inverted U shape can be a step backward. Six weeks is an arbitrary term but sufficient to pass the steady state period and collect data from several comparable days.

Summary

Cannabidiol is a compound with a mild safety profile and a narrow but strong evidence base. The strong part concerns drug-resistant epilepsies and individual trials on situational anxiety. Everything else relies on case series, cell studies, or nothing verifiable.

From this editorial, numbers without sources disappeared: bioavailability tables, market percentages from unavailable reports, customer satisfaction rates, and values describing entourage effect strength. Remaining are those that can be checked and sentences stating plainly what was not measured. We continue developing the Q&A set in the largest CBD FAQ collection.

If you start, reduce the decision to three steps. Choose a product with a certificate of analysis for the correct batch. Start with a small portion taken with a fatty meal at a fixed time. Give yourself several weeks and record effects instead of relying on memory. With chronic drugs, talk to your doctor or pharmacist first.

You can find industrial hemp oils with batch certificates in the oils category at u Bucha store.

Frequently Asked Questions

What is CBD in the simplest terms?

Cannabidiol is a compound from industrial hemp that does not intoxicate. It does not stimulate the CB1 receptor like THC but changes how this receptor responds to the body’s own transmitters (Laprairie 2015). Beyond the endocannabinoid system, it has been described to have several other molecular targets, but the translation to clinical effect remains poorly documented.

Is CBD legal in Poland in 2026?

Yes. Cannabidiol does not appear in any controlled substances lists, and products from industrial hemp are legal as long as the sum of delta-9-THC and THCA does not exceed 0.3% of dry mass. The basis is art. 4 point 5 of the Act on Counteracting Drug Addiction as in force since May 7, 2022.

How fast does CBD work after intake?

After an oral dose, blood concentration peaks after about 4-5 hours (Taylor 2018). A pharmacokinetics review reports time to maximum concentration ranging from zero to four hours depending on the administration route, with inhalation being the fastest (Millar 2018). Subjective sensation can occur earlier than peak concentration.

What CBD doses were used in studies?

In trials on public speaking anxiety, a single 300 mg dose was effective, while 150 mg, 600 mg, and 900 mg doses did not differ from placebo. In drug-resistant epilepsy, 20 mg per kilogram of body weight daily was used under medical supervision. No reference dose for non-medical use has been established.

Does CBD cause addiction or intoxication?

It does not intoxicate because it does not stimulate the CB1 receptor as THC does. No signals of addiction potential have been described, and a clinical data review indicates the most common side effects are fatigue, diarrhea, and changes in appetite and body weight (Iffland and Grotenhermen 2017). This is a mild but not zero profile.

How to choose a good CBD oil?

Check the certificate of analysis for the batch number on the label, not a generic certificate for the entire product line. It should provide cannabinoid contents and test results for heavy metals, pesticides, and solvent residues. Forms mainly differ in dosing precision, so it is easier to control oil in drops than gummies at the start.

Does CBD interact with medications?

Yes. Cannabidiol affects CYP3A4 and CYP2C19 enzymes and P-glycoprotein, so the risk of interactions with commonly used drugs is high (Brown and Winterstein 2019). Review authors recommend considering a lower dose of the primary drug or alternative therapy. Decide on combining with your doctor or pharmacist.

Is CBD safe for children and during pregnancy?

There is no data to consider use during pregnancy and breastfeeding safe, so it is not recommended. In children, the only approved and controlled use is for drug-resistant epilepsies, including Dravet syndrome, conducted exclusively under medical supervision.

This article is for informational and educational purposes and does not constitute medical advice. Before starting cannabis or CBD for therapeutic purposes, consult a doctor, especially if you take other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-09-22